Institution:
Experimental design developed to detect DNA methylation changes in patient T cells upon CAR transduction
EPICART
Development of a DNA methylation kit for predicting the response to CAR T-cell therapy, , already licensed to Pharmalink
Research Group:
Epigenètica del Càncer
Researcher/s:
Manel Esteller Badosa
Carlos García Prieto
Description:
Type of asset:
Service
Category:
Life Sciences
Problem:
Urgent need to predict the intensity and duration of the CAR T-cell therapy response, and the risk to develop severe adverse effects
Solution:
Personalized medicine, a diagnostic kit that predicts response and toxicity of CAR T-cell therapy with >80% accuracy
Aplication areas:
Cancer therapy
Novelty:
DNA methylation can predict clinical outcome and survival to CAR T-cell therapy
Protection:
Patented (EP21382168.9; EP21382815.5; PCT/EP2022/054803)
Target market:
Pharmaceutical companies
Keywords:
Personalised medicine, cancer epigenetics, leukemia, CAR-T Cell therapy
Technology Readiness Level (1-9): 4
Business Readiness Level (1-9): N/A
Impacted SDGs:
N/A
More information
if you want to know more about this project do not hesitate to contact us